Suppr超能文献

口服纯化的脂蛋白OspA可保护小鼠免受伯氏疏螺旋体的全身感染。

Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.

作者信息

Luke C J, Huebner R C, Kasmiersky V, Barbour A G

机构信息

Department of Microbiology, University of Texas Health Science Center at San Antonio 78284, USA.

出版信息

Vaccine. 1997 Apr-May;15(6-7):739-46. doi: 10.1016/s0264-410x(97)00219-3.

Abstract

The lipoprotein outer surface protein A (OspA) of the Lyme disease agent. Borrelia burgdorferi, has provided protection to mice and other animals against systemic infection when delivered orally as a recombinant protein in Escherichia coli, bacille Calmette. Guerin or Salmonella typhimurium. In the present study purified recombinant strain B31 OspA or outer surface protein D (OspD), another lipoprotein of B. burgdorferi, were administered either subcutaneously (s.c.) or orally without cell carrier or adjuvant to mice. In comparison to the OspD preparation, the OspA protein was 256-fold more resistant to trypsin. Whereas OspA in the suspension was in regular complexes of 17-25 nm in size, OspD formed amorphous globules of different sizes. Animals received a primary immunization and at least one booster. Mice immunized s.c. with either OspA or OspD had detectable antibodies to B. burgdorferi by enzyme-linked immunosorbent assay (ELISA), growth inhibition assay (GIA) and immunoblot. Delivered orally, OspA but not OspD elicited a specific antibody response, including IgA, as determined by these assays. The geometric mean titre of sera from mice who received 4 micrograms of OspA orally on days 1, 2, 4, 21 and 22 was 1470 by Ig ELISA, 320 by IgA ELISA and 128 by GIA. In infectious challenge experiments with B. burgdorferi strain Sh2-2-82 (OspA+ OspD- ) inoculated intradermally at 100 x the ID 50 all eight mice immunized with the 4 micrograms dose of OspA were protected, none of the mice immunized with the 4 micrograms dose of OspD were protected (P < 0.001 by Fisher exact test). These studies indicate that the lipoprotein OspA provides protection against systemic B. burgdorferi infection when delivered orally as a purified protein.

摘要

莱姆病病原体伯氏疏螺旋体的脂蛋白外表面蛋白A(OspA),以重组蛋白形式在大肠杆菌、卡介苗或鼠伤寒沙门氏菌中表达并经口服给予小鼠和其他动物后,能保护它们免受全身感染。在本研究中,将纯化的重组伯氏疏螺旋体菌株B31 OspA或另一种脂蛋白外表面蛋白D(OspD),在无细胞载体或佐剂的情况下皮下或口服给予小鼠。与OspD制剂相比,OspA蛋白对胰蛋白酶的抗性高256倍。悬浮液中的OspA呈大小为17 - 25nm的规则复合物,而OspD形成不同大小的无定形球体。动物接受一次初次免疫和至少一次加强免疫。通过酶联免疫吸附测定(ELISA)、生长抑制测定(GIA)和免疫印迹法,皮下接种OspA或OspD的小鼠体内可检测到抗伯氏疏螺旋体的抗体。经口服给予后,通过这些测定方法确定,OspA能引发特异性抗体反应,包括IgA,而OspD则不能。在第1、2、4、21和22天口服4微克OspA的小鼠血清的几何平均滴度,通过Ig ELISA为1470,通过IgA ELISA为320,通过GIA为128。在用伯氏疏螺旋体菌株Sh2 - 2 - 82(OspA + OspD - )进行的感染攻击实验中,以100倍半数感染剂量(ID50)皮内接种,接受4微克剂量OspA免疫的所有8只小鼠均受到保护,接受4微克剂量OspD免疫的小鼠无一受到保护(Fisher精确检验,P < 0.001)。这些研究表明,脂蛋白OspA作为纯化蛋白经口服给予时,能提供针对伯氏疏螺旋体全身感染的保护作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验